Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas

Acta Oncologica

Volumn 38, Issue 7, 1999, Pages 931-938

  Hennig, Elin M ^a   Kvinnsland, Stener ^b   Holm, Ruth ^c   Nesland, Jahn M ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b Institute for Cancer Research   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P21; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER IMMUNOLOGY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR VOLUME; WART VIRUS;

ADULT; AGED; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRIDAE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032751352     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432617     Document Type: Article

References (66)

1. White E. Life, death and the pursuit of apoptosis. Genes&Develop 1996; 10: 1-15.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
3. Barbareschi M, Caffo O, Veronese S, et al. A. Bcl-2 and p53 expression in node negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996; 27: 1149-55.
4. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen A-L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 540-8.
5. Ostrowski JL, Sawan A, Henry L, et al. P53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164: 75-81.
6. Horak E, Smith K, Bromley L, et al. Mutant p53, EOF receptor and c-erbB-2 expression in human cancer. Oncogene 1991; 6: 2277-84.
7. Bosari S, Lee AK. C, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat 1992; 421: 291-5.
8. Davidoff AM, Herndon JE, Glover NS, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 259-64.
9. Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al. TP53 mutation analyses on breast carcinomas: a study of paraffinembedded archival material. Br J Cancer 1996; 74: 555-61.
10. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Pari FT. P53 mutations and steroid receptor status in breast cancer. Cancer 1994; 73: 2147-56.
11. Wakasugi E, Kobayashi T, Tamaki Y, et al. P21 (Waf 1/Cip 1) and p53 protein expression in breast cancer. Am J Clin Path 1997; 107: 684-91.
12. Barbati A, Cosmi E, Sidoni A, et al. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Res 1997; 17: 401-6.
13. Sirvent JJ, Salvado MT, Santafe M, et al. P53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and cerbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 1995; 10: 531-9.
14. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21 undergo normal development, but are defective in G l checkpoint control. Cell 1995; 82: 675-84.
15. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF 1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G 1 cyclin dependent kinases. Cell 1993; 75: 805-16.
17. Michieli P, Chedid M, Lin D, Pierce J H, Mercer W E, Givol D. Induction of WAF 1/CIP 1 by a p53 independent pathway. Cancer Res 1994; 54: 3391-5.
18. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53 independent pathway for upregulation of SDI 1/CIP 1/WAF 1/p21 RNA in human cells. Mol Carcinogen 1994; II: 59-64.
19. Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF 1/CIP 1 protein and apoptosis in human T-cell leukemia virus type 1-transformed lymphocytes after treatment with adriamycin by using a p53 independent pathway. Proc Nail Acad Sci USA 1996; 93: 265-8.
20. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 1991; 65: 6671-6.
21. Thomas M, Massimi P, Jenkins J, Banks L. HPV 18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 1995; 10: 261-8.
22. Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-4.
23. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO 1989; 8: 4099-105.
24. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV 16 E7 oncoprotein. Genes & Develop 1997; II: 2090-100.
25. Jones DL, Alani RM, Münger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21 Cipl-me.diated inhibition of cdk 2. Genes&Develop 1997; 11: 2101-11.
26. Scholes AG, Liloglou T, Snijders PJ, et al. P53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck. Int J Cancer 1997; 71: 797-9.
27. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995; 63: 639-45.
28. Barten M, Ostwald C, Milde-Langosch K, Muller P, .Wukasch Y, Loning T. HPV DNA and p53 alterations in oropharyngeal carcinomas. Virchows Arch 1995; 427: 153-7.
29. Suzuki T, Shidara K, Hara F, Nakajima T. High frequency of p53 abnormality in laryngeal cancers of heavy smokers and its relation to human papillomavirus infection. Jpn J Cancer Res 1994; 85: 1087-93.
30. Shnitman Magal S, Jackman A, Pei XF, Schlegel R, Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 1998; 75: 96-104.
31. Craigo J, Hopkins M, de Lucia A. Uterine cervix adenocarcinoma with both human papillomavirus type 18 and the tumor suppressor gene p53 mutation from a woman having an intact hymen. Gynecol Oncol 1995; 59: 423-6.
32. Xu C, Meikrantz W, Schlegel R, Sager R. The human papilloma virus 16 E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc Natl Acad Sci USA 1995; 92: 7829-33.
33. Dalai S, Gao Q, Androphy EJ, Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 1996; 70: 683-8.
34. Slamon DJ, Clark GM, Wong SO, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
35. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.
36. Willsher PC, Beaver J, Finder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40: 251-5.
37. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
38. Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996; 16: 2295-300.
39. Imoto S, Ohkura H, Sugano K, et al. Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoessay. Jpn J Clin Oncol 1998; 28: 92-6.
40. Barbareschi M, Leonard! E, Mauri FA, Serio G, Dalla Palma P. P53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemically study including correlations with receptor status, proliferation markers and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98: 408-18.
41. Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM. Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res&Treatment 1999; 53: 121-35.
42. Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. 1: The value of histological grade in breast cancer. Experience from a large study long-term follow-up. Histopathology 1991; 19:403-10.
43. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699703.
44. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006-10.
45. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
46. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen A-L. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997; 181: 140-5.
47. Walker RA, Dearing SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 1991; 165: 203-11
48. Hurlimann J, Chaubert P, Benhattar J. P53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology technique. Mod Pathol 1994; 7: 423-8.
49. Davidoff AM, Humphrey PA, Igelhart JD, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006-10.
50. Davidoff AM, Herndon JE, Glover NS, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 259-64.
51. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale A-L, Trope C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage 1 carcinomas. J Pathol 1997; 181: 158-65.
52. Cattoretti G, Rilke F, Andreola S, et al. P53 expression in breast cancer. Int J Cancer 1988; 41: 178-83.
53. Nuorva K, Soini Y, Kamel D, et al. P53 protein accumulation and the presence of human papillomavirus DNA in bronchioalveolar carcinoma correlate with poor prognosis. Int J Cancer 1995; 64: 424-9.
54. Ikenberg H, Matthay K, Schmitt B, et al. P53 mutation and MDM2 amplification are rare even in human papillomavirusnegative cervical carcinomas. Cancer 1995; 76: 57-66.
55. Villuendas R, Pezzella F, Gatter K, et al. P21WAF1/CIP1 and M DM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53 +, MDM2-, p21 immunophenotype associated with missense p53 mutations. J Pathol 1997; 181: 51-61.
56. Ohashi K, Nemoto T, Eishi Y, Matsuno A, Nakamura K, Hirokawa K. Expression of the cyclin dependent kinase inhibitor p21WAF/CIPl in oesophageal squamous cell carcinomas. Virchows Arch 1997; 430: 389-95.
57. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-I/CIP 1) during differentiation. Oncogene 1994; 9: 3389-96.
58. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-9.
59. Bebenek M, Bar JK, Harlozinska A, Sedlacznek P. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticancer Res 1998; 18: 619-23.
60. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 199S; 16: 462-9.
61. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-2.
62. Seidman AD, Baselga J, Yao TJ, et al. HER-2/neu overexpression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 15: 104.
63. Lowe SW, Bodis S, McClathey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
64. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72-9.
65. Bhalla K, Harris WB. Molecular and biological determinants of neoadjuvant chemotherapy of locoregional breast cancer. Sem Oncol 1998; 25: 19-24.
66. Conrad M, Goldstein D, Andresson T, Schlegel R. The E5 protein of HPV 6, but not HPV 16 associates efficiently with cellular growth factor receptors. Virology 1994; 200: 796-800.